Transcobalamin II deficiency in twins with a novel variant in the TCN2 gene: case report and review of literature.


Journal

Journal of pediatric endocrinology & metabolism : JPEM
ISSN: 2191-0251
Titre abrégé: J Pediatr Endocrinol Metab
Pays: Germany
ID NLM: 9508900

Informations de publication

Date de publication:
26 Nov 2020
Historique:
received: 29 02 2020
accepted: 08 06 2020
pubmed: 26 8 2020
medline: 28 8 2021
entrez: 26 8 2020
Statut: ppublish

Résumé

Objectives Transcobalamin II (TC) is an essential plasma protein for the absorption, transportation, and cellular uptake of cobalamin. TC deficiency presents in the first year of life with failure to thrive, hypotonia, lethargy, diarrhea, pallor, mucosal ulceration, anemia, pancytopenia, and agammaglobulinemia. Herein, we present TC deficiency diagnosed in two cases (twin siblings) with a novel variant in the TCN2 gene. Case presentation 4-month-old twins were admitted with fever, respiratory distress, vomiting, diarrhea, and failure to thrive. Physical examination findings revealed developmental delay and hypotonia with no head control, and laboratory findings were severe anemia, neutropenia, and hypogammaglobulinemia. Despite normal vitamin B12 and folate levels, homocysteine and urine methylmalonic acid levels were elevated in both patients. Bone marrow examinations revealed hypocellular bone marrow in both cases. The patients had novel pathogenic homozygous c.241C>T (p.Gln81Ter) variant in the TCN2 gene. In both cases, with intramuscular hydroxycobalamin therapy, laboratory parameters improved, and a successful clinical response was achieved. Conclusions In infants with pancytopenia, growth retardation, gastrointestinal manifestations, and immunodeficiency, the inborn error of cobalamin metabolism should be kept in mind. Early diagnosis and treatment are crucial for better clinical outcomes. What is new? In literature, to date, less than 50 cases with TC deficiency were identified. In this report, we presented twins with TCN2 gene mutation. Both patients emphasized that early and aggressive treatment is crucial for achieving optimal outcomes. In this report, we identified a novel variation in TCN2 gene.

Identifiants

pubmed: 32841161
doi: 10.1515/jpem-2020-0096
pii: /j/jpem.ahead-of-print/jpem-2020-0096/jpem-2020-0096.xml
doi:
pii:

Substances chimiques

Codon, Nonsense 0
TCN2 protein, human 0
Transcobalamins 0
Hydroxocobalamin Q40X8H422O

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1487-1499

Auteurs

Engin Kose (E)

Department of Pediatric Metabolism and Nutrition, Ankara University Faculty of Medicine, Ankara, Turkey.

Ozge Besci (O)

Department of Pediatrics, Dr. Behçet Uz Children Research and Training Hospital, Izmir, Turkey.

Elif Gudeloglu (E)

Department of Pediatrics, Dr. Behçet Uz Children Research and Training Hospital, Izmir, Turkey.

Suzan Suncak (S)

Department of Pediatrics, Dr. Behçet Uz Children Research and Training Hospital, Izmir, Turkey.

Yesim Oymak (Y)

Department of Pediatric Hematology, Dr. Behçet Uz Children Research and Training Hospital, Izmir, Turkey.

Selime Ozen (S)

Department of Pediatric Immunology and Allergy, Dr. Behçet Uz Children Research and Training Hospital, Izmir, Turkey.

Rana Isguder (R)

Department of Pediatrics, Dr. Behçet Uz Children Research and Training Hospital, Izmir, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH